Related Experiment Video
Updated: Jul 1, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular
Benyi He1,2, Zehao Zheng1,2, Junyu Gan1,2
1Department of Liver Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dongfeng East Road, Guangzhou, 510060, China.
Background:
The role of adjuvant systemic therapy after resection following conversion therapy in patients with hepatocellular carcinoma (HCC) rendered resectable by transarterial therapy combined with systemic therapy remains unclear. This study aimed to evaluate the impact of adjuvant systemic therapy on survival outcomes in real-world practice.
Methods:
We retrospectively analyzed patients with initially unresectable HCC who underwent curative-intent resection after successful first-line transarterial therapy combined with systemic therapy between January 2018 and December 2023. Postoperative management included either adjuvant systemic therapy or active surveillance. Propensity score matching (1:2) was applied to balance baseline characteristics. Overall survival (OS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier methods and compared by log-rank tests. Subgroup and recurrence pattern analyses were also performed.
Results:
Among 496 eligible patients, 120 received adjuvant systemic therapy and 376 underwent active surveillance. After matching, 326 patients were included (116 vs. 210). Adjuvant systemic therapy was associated with significantly improved OS (HR 0.58, 95% CI 0.38-0.89; p = 0.01) and RFS (HR 0.64, 95% CI 0.48-0.84; p = 0.002). Survival benefit of adjuvant systemic therapy was observed in patients with BCLC stage C disease (OS: HR 0.53, 95% CI 0.31-0.90, p = 0.02; RFS: HR 0.61, 95% CI 0.43-0.87, p = 0.007) and in those with BCLC stage A or B disease exceeding the up-to-seven criteria (OS: HR 0.46, 95% CI 0.22-0.95, p = 0.03; RFS: HR 0.56, 95% CI 0.34-0.91, p = 0.02). Multivariable analysis identified adjuvant systemic therapy as an independent predictor of improved OS and RFS.
Conclusions:
In patients undergoing resection following conversion therapy for initially unresectable HCC, adjuvant systemic therapy was associated with improved survival, particularly among those with high-risk disease features.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:21Cancer Survival Analysis
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...